A National Roadmap to Secure Life-Saving Clinical Trials for Children with Cancer

While Australia has a world-class track record for adult cancer trials, we are falling behind when it comes to kids. We have the expertise and the technology, but right now, that isn't translating into enough trial options for the families who desperately need them. Here is how leading experts are proposing we rewrite the rules to give every Australian child a fighting chance.

For some children with cancer, a clinical trial may be their best – or only – treatment option, yet too often the right trial is not available in Australia.

We are world-class at attracting adult cancer trials and have built one of the most advanced paediatric oncology ecosystems anywhere, yet industry-sponsored paediatric oncology trials remain limited in Australia.

Australia has the capability – now is the time to translate that capability into bringing more industry-led paediatric oncology trials to Australia for children with cancer.

To advocate for change, ANZCHOG Chair Assoc. Prof. Andy Moore recently co-signed an important white paper assembled by Biointelect, alongside Prof. Louis Chesler of the Children’s Cancer Institute and Liz de Somer of Medicines Australia. The paper details a comprehensive roadmap built on four core recommendations to increase industry investment and trial access.

“Access to novel treatments, through both industry-sponsored early-phase trials and international cooperative group trials, is critical to improving outcomes further. Australia has the expertise, but requires investment and strategic reform to leverage that expertise and bring more trials of the most promising treatments to Australia.”

National consortium to align stakeholders and unlock opportunities for industry engagement

Australia’s paediatric oncology landscape features established research networks and precision medicine programs, but it remains fragmented across different institutions. This fragmentation limits international awareness of our clinical capabilities. The white paper recommends establishing a nationally coordinated consortium to present a unified entry point for global sponsors. ANZCHOG is exceptionally well placed to lead this initiative and align stakeholders around shared priorities.

Integrated data infrastructure to strengthen evidence generation and clinical utility

Australia possesses advanced data records for children with cancer, but these datasets are often siloed. Integrating existing assets like the Zero Childhood Cancer Program, the Cancer Information Registry for Children and Adolescents in Australia, and the Secured Access to Innovative Medicines for Children, Adolescents and Young Adults with Cancer program would significantly strengthen our evidence generation. Connecting these platforms will provide clinicians with real time data to inform treatment decisions and support clinical trial recruitment

Equitable access through decentralised trial delivery

Geography remains a major barrier for families needing to access clinical trials. Expanding decentralised trial delivery (such as teletrials and shared care approaches) is essential to reduce the travel burden on families. Leveraging regional healthcare networks to support trial activities closer to home ensures that every child has an opportunity to participate in research regardless of their location.

A clearer policy and commercial pathway can improve Australia’s competitiveness

Sponsors are more likely to bring trials to Australia when there is a clear pathway to market. Paediatric therapies are frequently designated as orphan drugs, making conventional evidence requirements difficult to satisfy. The white paper calls for regulatory and reimbursement frameworks to align with international best practices, including adopting age agnostic Pharmaceutical Benefits Scheme listings and providing clarity on the role of real world evidence.

Improving access to innovative therapies requires a collective effort across the entire healthcare ecosystem. We invite clinicians, researchers, policymakers, and advocates to review the full recommendations and join us in making Australia a premier destination for paediatric oncology trials.

National Paediatric Oncology
Industry-sponsored Clinical Trial Roundtable

Building a Future of Life-Saving Clinical Trials for Children with Cancer

Share the Post:

Related Posts